

Anti-CD79B (Polatuzumab), Humanized Antibody

rev 10/20

CATALOG NO.: A2178-100 (100 µg)

BACKGROUND DESCRIPTION: The research-grade biosimilar is a recombinant antibody to Polatuzumab without the drug conjugation. CD79B is a transmembrane protein that plays an essential role in B-cell receptor signaling and is highly expressed on the surface of tumorigenic cells. The original antibody-drug conjugate (Polatuzumab Vedotin) consists of Anti-CD79B humanized monoclonal antibody that is linked to a microtubule disrupting agent monomethyl auristatin E (MMAE) via a protease-cleavable linker. Upon internalization in the cell, the MMAE is detached from the antibody due to proteolytic cleavage. The MMAE then disrupts the microtubule network, which causes cell cycle arrest and apoptosis of tumorigenic cells. The original ADC has been approved by the FDA to treat patients with relapsed or refractory diffuse large B-cell lymphoma in combination with Bendamustine and Rituximab.

ALTERNATE NAMES: B29, IGB, AGM6, fcu 2711, Ro 5541077-000, DCDS4501A, RG7596

ANTIBODY TYPE: Monoclonal

HOST/ISOTYPE: Recombinant / IgG1, kappa

SOURCE: CHO cells

IMMUNOGEN: Human CD79B

CAS NUMBER: 1313206-42-6

MOLECULAR WEIGHT: 149.9 kDa

PURIFICATION: Protein A purified

FORM: Liquid

FORMULATION: In PBS, pH 7.5

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at -80°C. Avoid freeze/thaw cycles

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-CD30 (Brentuximab), Chimeric Antibody (A2177)
 Anti-CD20 (Rituximab), Chimeric Antibody (A1049)
 Anti-CD20 (Ofatumumab), Human IgG1 Antibody (A2172)
 Anti-PD-1 (Camrelizumab), Humanized Antibody (A2132)
 Anti-PD-1 (Sintilimab), Human IgG4 Antibody (A2156)

FOR RESEARCH USE ONLY! Not to be used on humans.